ClinicalTrials.gg
Not yet recruitingNCT06787807Updated Jan 22, 2025

Proteomic Analysis of Patients Undergoing Bariatric Surgery

An interventional study of bariatric surgery in Obesity, Colon Cancer and Thyroid Cancer, sponsored by Universidade Federal de Pernambuco. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Universidade Federal de Pernambuco · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The expression of proteins in the blood of obese individuals is different from the expression of proteins in healthy individuals, and is also different in individuals after bariatric surgery. Therefore, this research aims to better understand protein expression in patients indicated for surgical treatment of obesity, evaluating the pre-operative and post-operative status. The objective of this research is to better understand protein expression in patients indicated for surgical treatment of obesity, evaluating the pre-operative and post-surgery status.

Read the detailed description

The objective of this study is to analyze the Proteomics of obese patients in the preoperative context of bariatric surgery to evaluate which are the up-regulated proteins - potentially related to oncogenic metabolic pathways - and also the down-regulated proteins in the context of obesity - potentially protective in the context of cancer. As well as, evaluate the variation of these proteins, as well as the metabolic pathways with which they are associated, after weight loss promoted by bariatric surgery, in the period of 01 year after this intervention.

The proteomic study will be carried out based on the formation of pools organized based on the patients' pre- and postoperative similarities. Proteomic analyzes will be carried out on a high-performance liquid chromatography system (nanoUPLC) model Acquity Mclass, Waters. Coupled to a Quadrupole Mass Spectrometer-Time of Flight (QToF) Model Sunapt Xs, Waters. Finally, the raw data (raw mass spectra) will be analyzed by the PROGENESIS QI software (Waters) to identify the proteins.

02

Conditions studied

  • Obesity
  • Colon Cancer
  • Thyroid Cancer
  • Esophageal Cancer
  • Pancreatic Cancer
  • Gastric Cancer
  • Potmenopausal Breast Cancer
  • Endometrial Cancer
  • Liver Cancer
  • Gallbladder Cancer
  • Prostate Cancer
  • Ovarian
  • Kidney Cancer
  • Multiple Myeloma
  • Meningioma
  • Breast Cancer
  • Ovarian Cancer

Keywords

  • obesity
  • cancer
  • bariatric surgery
  • proteomics
  • biomarkers
  • mass spectrometry
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 103 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Universidade Federal de Pernambuco is the lead sponsor of 166 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients over 18 years of age with a above 35 kg/m² associated with comorbidity or BMI above 40 kg/m² without comorbidities,

Exclusion criteria

Exclusion Criteria:

  • Patients with a previous history of cancer;
  • Underage patients
  • Patients with other diseases predisposing to the development of cancer: cirrhosis, ulcerative colitis, Barrett's esophagus, etc.
  • Patients who have previously undergone bariatric surgery;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (estimated)

Study arms

  • Experimental
    women with insulin resistance

    An analysis was made of patients with severe steatosis, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

  • Experimental
    patients with severe steatosis

    An analysis was made of patients with severe steatosis, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

  • Experimental
    General patients with insulin resistance

    An analysis was made of patients, among men and women, with insulin resistance, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

  • Experimental
    Patients with above average CRP

    An analysis was carried out of patients with CRP above the average, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

  • Experimental
    Patients with grade 1 obesity

    An analysis was made of patients with grade 1 obesity, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

  • Experimental
    Patients with grade 2 obesity

    An analysis was made of patients with grade 2 obesity, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

  • Experimental
    Patients with grade 3 obesity

    An analysis was made of patients with grade 3 obesity, among patients undergoing bariatric surgery

    Procedure: bariatric surgery

Interventions

  • Procedurebariatric surgery

    sleeve gastrectomy

    Also known as: sleeve gastrectomy

06

What researchers measure

Primary outcomes

  1. Number of patients with reduced initially upregulated oncogenic proteins

    reduction of proteins potentially involved in oncogenic metabolic pathways, initially upregulated in the context of obesity

    Time frame: 1 year after bariatric surgery

07

Study locations

1 site
  • Hospital das clínicas da UFPE
    Recife, Pernambuco 50670901, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — We are still checking pertinent information for sharing

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06787807
Responsible party
Alvaro Ferraz (Full professor and head of the general surgery service at UFPE, Universidade Federal de Pernambuco) — Principal investigator
First posted
Jan 22, 2025
Start date
Jun 10, 2025 (estimated)
Primary completion
Sep 9, 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 22, 2025

Study contacts

Luiz Henrique A Bandeira, Medicine student
Contact
luiz.bandeira@ufpe.br
5581987082731
Júlia M Lins, medicine student
Contact
julia.lins@upe.br
5581996906749
Álvaro B Ferraz, Doctor
principal investigator · UFPE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion